{"id":206953,"name":"BOEHRINGER INGELHEIM","slug":"boehringer-ingelheim","state":"DC","country":"United States of America","description":"pharmaceutical company focused on innovative therapies for diseases w/o treatment option","totalSpending":1690000,"filings":25,"yearlySpending":[{"year":2020,"income":90000},{"year":2021,"income":360000},{"year":2022,"income":390000},{"year":2023,"income":290000},{"year":2024,"income":280000},{"year":2025,"income":280000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["TARPLIN, DOWNS & YOUNG, LLC"],"lobbyists":["RAISSA DOWNS","JENNIFER YOUNG","MICHELLE EASTON","ELIZABETH MURRAY","CHARLOTTE IVANCIC","PAMELA SMITH","EMILY MURRY","KIMBERLY BRANDT","MARGARET JOSEPH","PETER FISE","LAURA FRIEDEL","PARICK CARROLL"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Prescription drug access and affordability, FDA user fee reauthorization","Prescription drug access and affordability, FDA user fee reauthorization","Prescription drug access and affordability, FDA user fee reauthorization","Medicaid value based payment proposed rule","government funding\nH.R. 8337 - Continuing Appropriations Act of 2021"]}